Reports Q2 revenue $23.52M, consensus $23.08M. “We are pleased with the continued momentum in our business through the second quarter of 2025, as we made significant progress across a number of key initiatives to position NeuroPace (NPCE) for sustained long-term growth,” said Joel Becker, CEO. “We are advancing our strategy, driving increased access to and adoption of RNS therapy and supporting operating leverage as we scale.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NPCE Upcoming Earnings Report: What to Expect?
- NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- NeuroPace Appoints New CFO Amid Strategic Shift
- NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed